Civica Rx to launch 20 generic drugs in 2019

A new not-for-profit startup aimed at producing generic drugs will introduce 20 products in 2019, Reuters reported. The supplier, Civica Rx, initially expected to offer just 14 drugs in 2019, but will now likely exceed that after working with companies to produce additional medicines, company officials told Reuters.

Civica Rx was launched in September 2018 by several health foundations and hospital systems, including Intermountain Healthcare, Mayo Clinic, Trinity Health and more, to develop generic drugs that would address drug shortages and counter rising drug prices. The group has raised more than $160 million from its members, Reuters reported.

Over the next three to five years, Civica Rx plans to offer up to 100 generic medicines that are critical to its member hospitals. Member hospitals will pay the cost of drugs purchased and a fee to Civica based on their size, according to Reuters. The first medicines will be available at locations in New Jersey, Pennsylvania and North Carolina, and the group is negotiating prices with manufacturers in return for commitments to purchase the products for five to 10 years.

U.S. hospitals have faced severe shortages of commonly-used medicines, including anesthetics, intravenous saline and chemotherapies, over the last few years, sometimes accompanied by steep price increases. Hospitals have faced deep impacts from rising drug costs and shortages, according to a recent report, even turning to alternative therapies and treatments to accommodate.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”